Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind placebo-controlled trial of NV1FGF in critical limb ischemia
2006-006277-24Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jul 2007
- Modality
- Gene Therapies, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic limb-threatening ischemia (CLTI) comparing NV1FGF with Placebo (2 arms). Primary endpoint: Primary composite endpoint of major amputation or death. Started Jul 2007; status: completed.
02
Drugs
Riferminogene pecaplasmid
03
Conditions
chronic limb-threatening ischemia (CLTI)
Beyond the preview
Go deeper on 2006-006277-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006277-24.